ARCT Arcturus Therapeutics

Arcturus Reports Positive Interim Phase 2 Data for ARCT-810 in OTC Deficiency

Arcturus announced encouraging interim Phase 2 results for ARCT-810 in OTC deficiency, showing it was generally safe and well tolerated while reducing/maintaining fasting ammonia and glutamine levels within normal ranges. The company also plans to integrate next-generation candidate ARCT-2601 (using LUNAR 2.0) into the ongoing Phase 2 study near year-end 2026 following favorable FDA feedback.

Arcturus (ARCT) to Present ARCT-810 Phase 2 Data in OTC Deficiency on 2026-09-23

Arcturus will host a virtual presentation on September 23, 2026 providing an overview of the ARCT-810 Phase 2 clinical program for ornithine transcarbamylase (OTC) deficiency and its mRNA liver therapeutics platform. A press release summarizing the presentation will be issued beforehand. Expert Marshall Summar, M.D. will participate.

Arcturus ARCT-032 Phase 2 interim shows mucus reduction in Class I CF

Interim Phase 2 data from six Class I CF adults treated with 10 mg ARCT-032 for 28 days showed mucus plug and volume reductions in four of six participants on AI-enhanced HRCT. Exploratory FEV1 analysis suggested directional lung-function improvement. The company plans to start a 12-week safety and preliminary efficacy study in up to 20 CF participants in the first half of 2026.